On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance

Current Drug Metabolism

Volumn 10, Issue 9, 2009, Pages 981-997

  Van Asseldonk, Dirk P ^a   De Boer, Nanne K H ^a   Peters, Godefridus J ^a   Veldkamp, Agnes I ^a   Mulder, Chris J ^a   Van Bodegraven, Ad A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Azathioprine; Drug interactions; Drug intolerance; Inflammatory bowel disease; Mercaptopurine; Pharmacology; Therapeutic drug monitoring; Thioguanine

Indexed keywords

ALLOPURINOL; ALPHA4 INTEGRIN; AZATHIOPRINE; BALSALAZIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENZYME; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INFLIXIMAB; INOSINATE DEHYDROGENASE; INOSINE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PREDNISOLONE; RIBAVIRIN; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

APOPTOSIS; BONE MARROW TOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; CROHN DISEASE; DNA METHYLATION; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG ERYTHROCYTE LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVITY; ENZYME LOCALIZATION; FOOD INTAKE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC SCREENING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLUENZA; KIDNEY GRAFT REJECTION; LEUKEMIA; LEUKOPENIA; LIVER PROTECTION; LIVER TOXICITY; LOW DRUG DOSE; NODULAR HYPERPLASIA; OXIDATIVE STRESS; PANCREATITIS; PHARMACOGENOMICS; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS; BIOTRANSFORMATION; DRUG INTERACTIONS; DRUG MONITORING; GASTROINTESTINAL AGENTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; PURINES; RISK ASSESSMENT; RISK FACTORS; SULFHYDRYL COMPOUNDS; TREATMENT OUTCOME;

EID: 76749153792     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009790711887     Document Type: Review

References (217)

1. Elion, G.B. The purine path to chemotherapy. Science, 1989, 244(4900), 41-47.
2. Sandborn, W.; Sutherland, L.; Pearson, D.; May, G., Modigliani, R.; Prantera, C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev., 2000, (2), CD000545.
3. Timmer, A.; McDonald, J.W.; MacDonald, J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev., 2007, (1), CD000478.
4. Saibeni, S.; Virgilio, T.; D'Inca, R.; Spina, L.; Bortoli, A.; Paccagnella, M.; Peli, M.; Sablich, R.; Meucci, G.; Colombo, E.; Benedetti, G.; Girelli, C.M.; Casella, G.; Grasso, G.; de, F.R.; Vecchi, M. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig. Liver Dis., 2008, 40(10), 814-820.
5. Akobeng, A.K. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment. Pharmacol. Ther., 2008, 27(1), 11-18.
6. Gisbert, J.P.; Nino, P.; Cara, C.; Rodrigo, L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment. Pharmacol. Ther., 2008, 28(2), 228-238.
7. Ardizzone, S.; Maconi, G.; Russo, A.; Imbesi, V.; Colombo, E.; Bianchi, P.G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut, 2006, 55(1), 47-53.
8. Jharap, B.; Seinen, M.; Linskens, R.K.; Kneppelhout, J.K.; Mulder, C.J.; De Boer, N.K.; van Bodegraven, A.A. Predictors for failing thiopurine therapy in IBD patients; treated at an academic or general district hospital. Gastroenterology, 2008, 134(Suppl 4), A-206.
9. Dubinsky, M.C.; Vasiliauskas, E.A.; Singh, H.; Abreu, M.T.; Papadakis, K.A.; Tran, T.; Martin, P.; Vierling, J.M.; Geller, S.A.; Targan, S.R.; Poordad, F.F. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology, 2003, 125(2), 298-303.
10. Seiderer, J.; Zech, C.J.; Reinisch, W.; Lukas, M.; Diebold, J.; Wrba, F.; Teml, A.; Chalupna, P.; Stritesky, J.; Schoenberg, S.O.; Schima, W.; Goke, B.; Ochsenkuhn, T. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J. Hepatol., 2005, 43(2), 303-309.
11. Teml, A.; Schaeffeler, E.; Herrlinger, K.R.; Klotz, U.; Schwab, M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin. Pharmacokinet., 2007, 46(3), 187-208.
12. Sahasranaman, S.; Howard, D.; Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol., 2008, 64(8), 753-767.
13. Van Os, E.C.; Zins, B.J.; Sandborn, W.J.; Mays, D.C.; Tremaine, W.J.; Mahoney, D.W.; Zinsmeister, A.R.; Lipsky, J.J. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut, 1996, 39(1), 63-68.
14. Zimm, S.; Collins, J.M.; Riccardi, R.; O'Neill, D.; Narang, P.K.; Chabner, B.; Poplack, D.G. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N. Engl. J. Med., 1983, 308(17), 1005-1009.
15. Bronk, J.R.; Lister, N.; Shaw, M.I. Transport and metabolism of 6-thioguanine and 6-mercaptopurine in mouse small intestine. Clin. Sci. (Lond), 1988, 74(6), 629-638.
16. Lowe, E.S.; Kitchen, B.J.; Erdmann, G.; Stork, L.C.; Bostrom, B.C.; Hutchinson, R.; Holcenberg, J.; Reaman, G.H.; Woods, W.; Franklin, J.; Widemann, B.C.; Balis, F.M.; Murphy, R.F.; Adamson, P.C. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: a collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. Cancer Chemother. Pharmacol., 2001, 47(3), 199-205.
17. Deibert, P.; Dilger, K.; Fischer, C.; Hofmann, U.; Nauck, S.; Stoelben, S.; Kreisel, W. High variation of tioguanine absorption in patients with chronic active Crohn's disease. Aliment Pharmacol. Ther., 2003, 18(2), 183-189.
18. Lancaster, D.L.; Patel, N.; Lennard, L.; Lilleyman, J.S. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br. J. Clin. Pharmacol., 2001, 51(6), 531-539.
19. Brox, L.W.; Birkett, L.; Belch, A. Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer. Chemother. Pharmacol., 1981, 6(1), 35-38.
20. Rivard, G.E.; Lin, K.T.; Leclerc, J.M.; David, M. Milk could decrease the bioavailability of 6-mercaptopurine. Am. J. Pediatr. Hematol. Oncol., 1989, 11(4), 402-406.
21. Ansari, A.; Aslam, Z.; De Sica, A.; Smith, M.; Gilshenan, K.; Fairbanks, L.; Marinaki, A.; Sanderson, J.; Duley, J. Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment.. Pharmacol. Ther., 2008, 28(6), 749-757.
22. Eklund, B.I.; Moberg, M.; Bergquist, J., Mannervik, B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol. Pharmacol., 2006, 70(2), 747-754.
23. Scholar, E.M. and Calabresi, P. Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. Cancer Res., 1973, 33(1), 94-103.
24. Huh, K.; Yamamoto, I.; Gohda, E.; Iwata, H. Tissue distribution and characteristics of xanthine oxidase and allopurinol oxidizing enzyme. Jpn. J. Pharmacol., 1976, 26(6), 719-724.
25. Erb, N.; Harms, D.O.; Janka-Schaub, G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother. Pharmacol., 1998, 42(4), 266-272.
26. Lancaster, D.L.; Patel, N.; Lennard, L.; Lilleyman, J.S. Leucocyte versus erythrocyte thioguanine nucleotide concentrations in children taking thiopurines for acute lymphoblastic leukaemia. Cancer. Chemother. Pharmacol, 2002, 50(1), 33-36.
27. Montero, C.; Duley, J.A.; Fairbanks, L.D.; McBride, M.B.; Micheli, V.; Cant, A.J.; Morgan, G. Demonstration of induction of erythrocyte inosine monophosphate dehydrogenase activity in Ribavirin-treated patients using a high performance liquid chromatography linked method. Clin. Chim. Acta, 1995, 238(2), 169-178.
28. Duley, J.A. and Florin, T.H.J. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug. Monit, 2005, 27(5), 647-654.
29. Swann, P.F.; Waters, T.R.; Moulton, D.C.; Xu, Y.Z.; Zheng, Q.; Edwards, M.; Mace, R. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science, 1996, 273(5278), 1109-1111.
30. Somerville, L.; Krynetski, E.Y.; Krynetskaia, N.F.; Beger, R.D.; Zhang, W.; Marhefka, C.A.; Evans, W.E.; Kriwacki, R.W. Structure and dynamics of thioguanine-modified duplex DNA. J. Biol. Chem, 2003, 278(2), 1005-1011.
31. De Boer, N.K.; van Bodegraven, A.A.; Jharap, B.; De Graaf, P.; Mulder, C.J. Drug Insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol., 2007, 4(12), 686-694.
32. Karran, P. and Attard, N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat. Rev. Cancer, 2008, 8(1), 24-36.
33. Quemeneur, L.; Gerland, L.M.; Flacher, M.; Ffrench, M.; Revillard, J.P.; Genestier, L. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J. Immunol, 2003, 170(10), 4986-4995.
34. Daehn, I. and Karran, P. Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res., 2009, 69(6), 2393-2399.
35. Wang, H. and Wang, Y. 6-Thioguanine Perturbs Cytosine Methylation at the CpG Dinucleotide Site by DNA Methyltransferases in vitro and Acts as a DNA Demethylating Agent in vivo (dagger). Biochemistry, 2009, 48(10), 2290-2299.
36. Tidd, D.M.; Kim, S.C.; Horakova, K.; Moriwaki, A.; Paterson, A.R. A delayed cytotoxic reaction for 6-mercaptopurine. Cancer Res., 1972, 32(2), 317-322.
37. Allan, P.W. and Bennett, L.L., Jr. 6-Methylthioguanylic acid, a metabolite of 6-thioguanine. Biochem. Pharmacol., 1971, 20(4), 847-852.
38. Dervieux, T.; Blanco, J.G.; Krynetski, E.Y.; Vanin, E.F.; Roussel, M.F.; Relling, M.V. Differing contribution of thiopurine methyl transferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res., 2001, 61(15), 5810-5816.
39. Coulthard, S.A.; Hogarth, L.A.; Little, M.; Matheson, E.C.; Redfern, C.P.; Minto, L.; Hall, A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol. Pharmacol., 2002, 62(1), 102-109.
40. Vogt, M.H.; Stet, E.H.; De Abreu, R.A.; Bokkerink, J.P.; Lambooy, L.H.; Trijbels, F.J. The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts. Biochim. Biophys. Acta, 1993, 1181(2), 189-194.
41. Tiede, I.; Fritz, G.; Strand, S.; Poppe, D.; Dvorsky, R.; Strand, D.; Lehr, H.A.; Wirtz, S.; Becker, C.; Atreya, R.; Mudter, J.; Hildner, K.; Bartsch, B.; Holtmann, M.; Blumberg, R.; Walczak, H.; Iven, H.; Galle, P.R.; Ahmadian, M.R.; Neurath, M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest., 2003, 111(8), 1133-1145.
42. Poppe, D.; Tiede, I.; Fritz, G.; Becker, C.; Bartsch, B.; Wirtz, S.; Strand, D.; Tanaka, S.; Galle, P.R.; Bustelo, X.R.; Neurath, M.F. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol., 2006, 176(1), 640-651.
43. Thomas, C.W.; Myhre, G.M.; Tschumper, R.; Sreekumar, R.; Jelinek, D.; McKean, D.J.; Lipsky, J.J.; Sandborn, W.J.; Egan, L.J. Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J. Pharmacol. Exp. Ther., 2005, 312(2), 537-545.
44. Ben-Horin, S.; Goldstein, I.; Fudim, E.; Picard, O.; Yerushalmi, Z.; Barshack, I.; Bank, I.; Goldschmid, Y.; Meir, S.B.; Mayer, L.; Chowers, Y. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut, 2009, 58(3), 396-403.
45. Crawford, D.J.; Maddocks, J.L.; Jones, D.N.; Szawlowski, P. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J. Med. Chem., 1996, 39(14), 2690-2695.
46. Pearson, D.C.; May, G.R.; Fick, G.H.; Sutherland, L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Intern. Med., 1995, 123(2), 132-142.
47. Chan, G.L.; Erdmann, G.R.; Gruber, S.A.; Matas, A.J.; Canafax, D.M. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J. Clin. Pharmacol., 1990, 30(4), 358-363.
48. Sandborn, W.J.; Tremaine, W.J.; Wolf, D.C.; Targan, S.R.; Sninsky, C.A.; Sutherland, L.R.; Hanauer, S.B.; McDonald, J.W.; Feagan, B.G.; Fedorak, R.N.; Isaacs, K.L.; Pike, M.G.; Mays, D.C.; Lipsky, J.J.; Gordon, S.; Kleoudis, C.S.; Murdock, R.H. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology, 1999, 117(3), 527-535.
49. Garat, A.; Cauffiez, C.; Renault, N.; Lo-Guidice, J.M.; Allorge, D.; Chevalier, D.; Houdret, N.; Chavatte, P.; Loriot, M.A.; Gala, J.L.; Broly, F. Characterisation of novel defective thiopurine Smethyltransferase allelic variants. Biochem. Pharmacol., 2008, 76(3), 404-415.
50. Lennard, L.; Lilleyman, J.S.; Van Loon, J.; Weinshilboum, R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet, 1990, 336(8709), 225-229.
51. Clunie, G.P. and Lennard, L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford), 2004, 43(1), 13-18.
52. Collie-Duguid, E.S.; Pritchard, S.C.; Powrie, R.H.; Sludden, J.; Collier, D.A.; Li, T.; McLeod, H.L. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics, 1999, 9(1), 37-42.
53. Lennard, L. TPMT in the treatment of Crohn's disease with azathioprine. Gut, 2002, 51(2), 143-146.
54. Tai, H.L.; Krynetski, E.Y.; Yates, C.R.; Loennechen, T.; Fessing, M.Y.; Krynetskaia, N.F.; Evans, W.E. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet., 1996, 58(4), 694-702.
55. Schaeffeler, E.; Fischer, C.; Brockmeier, D.; Wernet, D.; Moerike, K.; Eichelbaum, M.; Zanger, U.M.; Schwab, M. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics, 2004, 14(7), 407-417.
56. Chang, J.G.; Lee, L.S.; Chen, C.M.; Shih, M.C.; Wu, M.C.; Tsai, F.J.; Liang, D.C. Molecular analysis of thiopurine Smethyltransferase alleles in South-east Asian populations. Pharmacogenetics, 2002, 12(3), 191-195.
57. Dubinsky, M.C.; Yang, H.; Hassard, P.V.; Seidman, E.G.; Kam, L.Y.; Abreu, M.T.; Targan, S.R.; Vasiliauskas, E.A. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology, 2002, 122(4), 904-915.
58. Roberts, R.L.; Gearry, R.B.; Bland, M.V.; Sies, C.W.; George, P.M.; Burt, M.; Marinaki, A.M.; Arenas, M.; Barclay, M.L.; Kennedy, M.A. Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultrahigh enzyme activity. Pharmacogenet. Genomics, 2008, 18(5), 434-438.
59. Yan, L.; Zhang, S.; Eiff, B.; Szumlanski, C.L.; Powers, M.; O'Brien, J.F.; Weinshilboum, R.M. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin. Pharmacol. Ther., 2000, 68(2), 210-219.
60. Winter, J.W.; Gaffney, D.; Shapiro, D.; Spooner, R.J.; Marinaki, A.M.; Sanderson, J.D.; Mills, P.R. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2007, 25(9), 1069-1077.
61. Lennard, L.; Chew, T.S.; Lilleyman, J.S. Human thiopurine methyltransferase activity varies with red blood cell age. Br. J. Clin. Pharmacol., 2001, 52(5), 539-546.
62. De Boer, N.K.; van Bodegraven, A.A.; De Graaf, P.; Van der Hulst, R.W.; Zoetekouw, L.; van Kuilenburg, A.B. Paradoxical Elevated Thiopurine S-Methyltransferase Activity After Pancytopenia During Azathioprine Therapy: Potential Influence of Red Blood Cell Age. Ther. Drug Monit., 2008, 30(3), 390-393.
63. Schwab, M.; Schaeffeler, E.; Marx, C.; Zanger, U.; Aulitzky, W.; Eichelbaum, M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology, 2001, 121(2), 498-499.
64. Black, A.J.; McLeod, H.L.; Capell, H.A.; Powrie, R.H.; Matowe, L.K.; Pritchard, S.C.; Collie-Duguid, E.S.; Reid, D.M. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann. Intern. Med., 1998, 129(9), 716-718.
65. Derijks, L.J.J.; Gilissen, L.P.L.; Engels, L.G.J.B.; Bos, L.P.; Bus, P.J.; Lohman, J.J.H.M.; Curvers, W.L.; Van Deventer, S.J.H.; Hommes, D.W.; Hooymans, P.M. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther. Drug. Monit., 2004, 26(3), 311-318.
66. Gilissen, L.P.L.; Derijks, L.J.J.; Bos, L.P.; Verhoeven, H.M.J.M.; Bus, P.J.; Hooymans, P.M.; Engels, L.G.J.B. Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients. Eur. J. Gastroenterol. Hepatol., 2004, 16(7), 705-710.
67. Colombel, J.F.; Ferrari, N.; Debuysere, H.; Marteau, P.; Gendre, J.P.; Bonaz, B.; Soule, J.C.; Modigliani, R.; Touze, Y.; Catala, P.; Libersa, C.; Broly, F. Genotypic analysis of thiopurine Smethyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology, 2000, 118(6), 1025-1030.
68. Palmieri, O.; Latiano, A.; Bossa, F.; Vecchi, M.; D'Inca, R.; Guagnozzi, D.; Tonelli, F.; Cucchiara, S.; Valvano, M.R.; Latiano, T.; Andriulli, A.; Annese, V. Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines' toxicity and efficacy. Aliment. Pharmacol. Ther., 2007, 26(5), 737-745.
69. Campbell, S.; Kingstone, K.; Ghosh, S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment. Pharmacol. Ther., 2002, 16(3), 389-398.
70. Ansari, A.; Arenas, M.; Greenfield, S.M.; Morris, D.; Lindsay, J.; Gilshenan, K.; Smith, M.; Lewis, C.; Marinaki, A.; Duley, J.; Sanderson, J. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther., 2008, 28(8), 973-983.
71. Hindorf, U.; Lindqvist, M.; Hildebrand, H.; Fagerberg, U.; Almer, S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2006, 24(2), 331-342.
72. Gisbert, J.P.; Nino, P.; Rodrigo, L.; Cara, C.; Guijarro, L.G. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am. J. Gastroenterol., 2006, 101(12), 2769-2776.
73. Relling, M.V.; Hancock, M.L.; Boyett, J.M.; Pui, C.H.; Evans, W.E. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood, 1999, 93(9), 2817-2823.
74. Chocair, P.R.; Duley, J.A.; Simmonds, H.A.; Cameron, J.S. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation, 1992, 53(5), 1051-1056.
75. Lowry, P.W.; Franklin, C.L.; Weaver, A.L.; Pike, M.G.; Mays, D.C.; Tremaine, W.J.; Lipsky, J.J.; Sandborn, W.J. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut, 2001, 49(5), 665-670.
76. Kwan, L.Y.; Devlin, S.M.; Mirocha, J.M.; Papadakis, K.A. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig. Liver Dis., 2008, 40(6), 425-432.
77. Baker, D.E. Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Rev. Gastroenterol. Disord., 2003, 3(3), 150-157.
78. Dubinsky, M.C.; Reyes, E.; Ofman, J.; Chiou, C.F.; Wade, S.; Sandborn, W.J. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol., 2005, 100(10), 2239-2247.
79. Van den Akker-Van Marle ME; Gurwitz, D.; Detmar, S.B.; Enzing, C.M.; Hopkins, M.M.; Gutierrez de Mesa, E.; Ibarreta, D. Costeffectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics, 2006, 7(5), 783-792.
80. Priest, V.L.; Begg, E.J.; Gardiner, S.J.; Frampton, C.M.; Gearry, R.B.; Barclay, M.L.; Clark, D.W.; Hansen, P. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics, 2006, 24(8), 767-781.
81. Winter, J.; Walker, A.; Shapiro, D.; Gaffney, D.; Spooner, R.J.; Mills, P.R. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther., 2004, 20(6), 593-599.
82. Lichtenstein, G.R.; Abreu, M.T.; Cohen, R.; Tremaine, W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology, 2006, 130(3), 940-987.
83. Travis, S.P.; Stange, E.F.; Lemann, M.; Oresland, T.; Chowers, Y.; Forbes, A.; D'Haens, G.; Kitis, G.; Cortot, A.; Prantera, C.; Marteau, P.; Colombel, J.F.; Gionchetti, P.; Bouhnik, Y.; Tiret, E.; Kroesen, J.; Starlinger, M.; Mortensen, N.J. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut, 2006, 55. Suppl. i16-i35.
84. Herrlinger, K.R. and Jewell, D.P. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment. Pharmacol. Ther, 2006, 24(10), 1403-1412.
85. Krenitsky, T.A.; Neil, S.M.; Elion, G.B.; Hitchings, G.H. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch. Biochem. Biophys., 1972, 150(2), 585-599.
86. Xu, P.; Huecksteadt, T.P.; Harrison, R.; Hoidal, J.R. Molecular cloning, tissue expression of human xanthine dehydrogenase. Biochem. Biophys. Res. Commun., 1994, 199(2), 998-1004.
87. Guerciolini, R.; Szumlanski, C.; Weinshilboum, R.M. Human liver xanthine oxidase: nature and extent of individual variation. Clin. Pharmacol. Ther., 1991, 50(6), 663-672.
88. Wong, D.R.; Derijks, L.J.; Den Dulk, M.O.; Gemmeke, E.H.; Hooymans, P.M. The role of xanthine oxidase in thiopurine metabolism: a case report. Ther. Drug Monit., 2007, 29(6), 845-848.
89. Kudo, M.; Moteki, T.; Sasaki, T.; Konno, Y.; Ujiie, S.; Onose, A.; Mizugaki, M.; Ishikawa, M.; Hiratsuka, M. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet. Genomics, 2008, 18(3), 243-251.
90. Smith, M.A.; Marinaki, A.M.; Arenas, M.; Shobowale-Bakre, M.; Lewis, C.M.; Ansari, A.; Duley, J.; Sanderson, J.D. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment. Pharmacol. Ther., 2009, 30(4), 375-384.
91. Wilson, J.M.; Young, A.B.; Kelley, W.N. Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes. N. Engl. J. Med, 1983, 309(15), 900-910.
92. Srivastava, T.; O'Neill, J.P.; Dasouki, M.; Simckes, A.M. Childhood hyperuricemia and acute renal failure resulting from a missense mutation in the HPRT gene. Am. J. Med. Genet., 2002, 108(3), 219-222.
93. Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol, 1992, 43(4), 329-339.
94. Peters, G.J. and Veerkamp, J.H. Purine and pyrimidine metabolism in peripheral blood lymphocytes. Int. J. Biochem., 1983, 15(2), 115-123.
95. Falta, M.T.; Atkinson, M.A.; Allegretta, M.; Vacek, P.M.; Albertini, R.J. Azathioprine associated T-cell mutations in insulindependent diabetes mellitus. Scand. J. Immunol., 2000, 51(6), 626-633.
96. Rice, S.C.; Vacek, P.; Homans, A.H.; Messier, T.; Rivers, J.; Kendall, H.; Finette, B.A. Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia. Cancer Res., 2004, 64(13), 4464-4471.
97. De Boer, N.K.; Van Asseldonk, D.P.; Van Bodegraven, A.A. On the malignant potential of thiopurine therapy. Blood, 2009, 113(24), 6258-6259.
98. Stocco, G.; Cheok, M.H.; Crews, K.R.; Dervieux, T.; French, D.; Pei, D.; Yang, W.; Cheng, C.; Pui, C.H.; Relling, M.V.; Evans, W.E. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther., 2009, 85(2), 164-172.
99. Sumi, S.; Marinaki, A.M.; Arenas, M.; Fairbanks, L.; Shobowale-Bakre, M.; Rees, D.C.; Thein, S.L.; Ansari, A.; Sanderson, J.; De Abreu, R.A.; Simmonds, H.A.; Duley, J.A. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet., 2002, 111(4-5), 360-367.
100. Gearry, R.B.; Roberts, R.L.; Barclay, M.L.; Kennedy, M.A. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics, 2004, 14(11), 779-781.
101. Marinaki, A.M.; Ansari, A.; Duley, J.A.; Arenas, M.; Sumi, S.; Lewis, C.M.; Shobowale-Bakre, E.; Escuredo, E.; Fairbanks, L.D.; Sanderson, J.D. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics, 2004, 14(3), 181-187.
102. Zelinkova, Z.; Derijks, L.J.; Stokkers, P.C.; Vogels, E.W.; Van Kampen, A.H.; Curvers, W.L.; Cohn, D.; Van Deventer, S.J.; Hommes, D.W. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprineinduced myelosuppression. Clin. Gastroenterol. Hepatol., 2006, 4(1), 44-49.
103. Hawwa, A.F.; Millership, J.S.; Collier, P.S.; Vandenbroeck, K.; McCarthy, A.; Dempsey, S.; Cairns, C.; Collins, J.; Rodgers, C.; McElnay, J.C. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol., 2008, 66(4), 517-528.
104. Van Dieren, J.M.; Van Vuuren, A.J.; Kusters, J.G.; Nieuwenhuis, E.E.; Kuipers, E.J.; Van der Woude, C.J. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut, 2005, 54(11), 1664.
105. Hindorf, U.; Lindqvist, M.; Peterson, C.; Soderkvist, P.; Strom, M.; Hjortswang, H.; Pousette, A.; Almer, S. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut, 2006, 55(10), 1423-1431.
106. Von Ahsen, N.; Armstrong, V.W.; Behrens, C.; Von Tirpitz, C.; Stallmach, A.; Herfarth, H.; Stein, J.; Bias, P.; Adler, G.; Shipkova, M.; Oellerich, M.; Kruis, W.; Reinshagen, M.; Schutz, E. Association of inosine triphosphatase 94C>A and thiopurine Smethyltransferase deficiency with adverse events and study dropouts under azathioprine therapy in a prospective Crohn disease study. Clin. Chem., 2005, 51(12), 2282-2288.
107. Van Dieren, J.M.; Hansen, B.E.; Kuipers, E.J.; Nieuwenhuis, E.E.; Van der Woude, C.J. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther., 2007, 26(5), 643-652.
108. Natsumeda, Y.; Ohno, S.; Kawasaki, H.; Konno, Y.; Weber, G.; Suzuki, K. Two distinct cDNAs for human IMP dehydrogenase. J. Biol. Chem., 1990, 265(9), 5292-5295.
109. Bremer, S.; Rootwelt, H.; Bergan, S. Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin. Chem., 2007, 53(6), 1023-1029.
110. Jackson, R.C.; Weber, G.; Morris, H.P. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature, 1975, 256(5515), 331-333.
111. Zimmermann, A.G.; Gu, J.J.; Laliberte, J.; Mitchell, B.S. Inosine-5′-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog. Nucleic Acid Res. Mol. Biol., 1998, 61, 181-209.
112. Albrecht, W.; Storck, M.; Pfetsch, E.; Martin, W.; Abendroth, D. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5′-monophosphate dehydrogenase in whole blood and isolated mononuclear cells. Ther. Drug Monit., 2000, 22(3), 283-294.
113. Haglund, S.; Taipalensuu, J.; Peterson, C.; Almer, S. IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol., 2008, 65(1), 69-77.
114. Lennard, L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J. Chromatogr., 1987, 42(3), 169-178.
115. Lennard, L. and Singleton, H.J. High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J. Chromatogr., 1992, 583(1), 83-90.
116. Keuzenkamp-Jansen, C.W.; De Abreu, R.A.; Bokkerink, J.P.; Trijbels, J.M. Determination of extracellular and intracellular thiopurines and methylthiopurines by high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 1995, 672(1), 53-61.
117. Hawwa, A.F.; Millership, J.S.; Collier, P.S.; McElnay, J.C. Development and validation of an HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells. J. Pharm. Biomed. Anal., 2009, 49(2), 401-409.
118. Dervieux, T. and Boulieu, R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin. Chem., 1998, 44(3), 551-555.
119. Shipkova, M.; Armstrong, V.W.; Wieland, E.; Oellerich, M. Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. Clin. Chem., 2003, 49(2), 260-268.
120. Vikingsson, S.; Carlsson, B.; Almer, S.H.; Peterson, C. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? Ther. Drug Monit., 2009, 31(3), 345-350.
121. De Graaf, P.; De Boer, N.K.; Jharap, B.; Mulder, C.J.; Van Bodegraven, A.A.; Veldkamp, A.I. Stability of thiopurine metabolites: a potential analytical bias. Clin. Chem., 2008, 54(1), 216-218.
122. Reinshagen, M.; Schutz, E.; Armstrong, V.W.; Behrens, C.; Von Tirpitz, C.; Stallmach, A.; Herfarth, H.; Stein, J.; Bias, P.; Adler, G.; Shipkova, M.; Kruis, W.; Oellerich, M.; Von Ahsen, N. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin. Chem., 2007, 53(7), 1306-1314.
123. Gisbert, J.P. 6-Thioguanine nucleotide (6-TGN) concentrations and efficacy of azathioprine (AZA) and mercaptopurine (MP) in inflammatory bowel disease: the METAZA study. J. Crohns and Colitis Supplements, 2008, 2(1), 7.
124. Cuffari, C.; Seidman, E.G.; Latour, S.; Theoret, Y. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can. J. Physiol. Pharmacol., 1996, 74(5), 580-585.
125. Warren, D.J.; Andersen, A.; Slordal, L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res., 1995, 55(8), 1670-1674.
126. Erdmann, G.R.; Steury, J.C.; Carleton, B.C.; Stafford, R.J.; Bostrom, B.C.; Canafax, D.M. Reversed-phase high-performance liquid chromatographic approach to determine total lymphocyte concentrations of 6-thioguanine, methylmercaptopurine and methylthioguanine in humans. J. Chromatogr., 1991, 571(1-2), 149-156.
127. Dervieux, T.; Chu, Y.; Su, Y.; Pui, C.H.; Evans, W.E.; Relling, M.V. HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin. Chem, 2002, 48(1), 61-68.
128. Cuffari, C.; Theoret, Y.; Latour, S.; Seidman, G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut, 1996, 39(3), 401-406.
129. Dubinsky, M.C.; Lamothe, S.; Yang, H.Y.; Targan, S.R.; Sinnett, D.; Theoret, Y.; Seidman, E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology, 2000, 118(4), 705-713.
130. Cuffari, C.; Hunt, S.; Bayless, T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut, 2001, 48(5), 642-646.
131. Ooi, C.Y.; Bohane, T.D.; Lee, D.; Naidoo, D.; Day, A.S. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment. Pharmacol. Ther., 2007, 25(8), 941-947.
132. Achkar, J.P.; Stevens, T.; Easley, K.; Brzezinski, A.; Seidner, D.; Lashner, B. Indicators of clinical response to treatment with sixmercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm. Bowel Dis., 2004, 10(4), 339-345.
133. Cuffari, C.; Dassopoulos, T.; Turnbough, L.; Thompson, R.E.; Bayless, T.M. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol., 2004, 2(5), 410-417.
134. Belaiche, J.; Desager, J.P.; Horsmans, Y.; Louis, E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand. J. Gastroenterol., 2001, 36(1), 71-76.
135. Reuther, L.O.; Sonne, J.; Larsen, N.E.; Larsen, B.; Christensen, S.; Rasmussen, S.N.; Tofteng, F.; Haaber, A.; Johansen, N.; Kjeldsen, J.; Schmiegelow, K. Pharmacological monitoring of azathioprine therapy. Scand. J. Gastroenterol., 2003, 38(9), 972-977.
136. Goldenberg, B.A.; Rawsthorne, P.; Bernstein, C.N. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am. J. Gastroenterol., 2004, 99(9), 1744-1748.
137. Wusk, B.; Kullak-Ublick, G.A.; Rammert, C.; Von Eckardstein, A.; Fried, M.; Rentsch, K.M. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur. J. Gastroenterol. Hepatol., 2004, 16(12), 1407-1413.
138. Osterman, M.T.; Kundu, R.; Lichtenstein, G.R.; Lewis, J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology, 2006, 130(4), 1047-1053.
139. Neurath, M.F.; Kiesslich, R.; Teichgraber, U.; Fischer, C.; Hofmann, U.; Eichelbaum, M.; Galle, P.R.; Schwab, M. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin. Gastroenterol. Hepatol., 2005, 3(10), 1007-1014.
140. Connell, W.R.; Kamm, M.A.; Ritchie, J.K.; Lennard-Jones, J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut, 1993, 34(8), 1081-1085.
141. Colonna, T. and Korelitz, B.I. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am. J. Gastroenterol., 1994, 89(3), 362-366.
142. Gilissen, L.P.; Derijks, L.J.; Verhoeven, H.M.; Bierau, J.; Hooymans, P.M.; Hommes, D.W.; Engels, L.G. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig. Liver. Dis., 2007, 39(2), 182-186.
143. Gisbert, J.P.; Luna, M.; Gonzalez-Lama, Y.; Pousa, I.D.; Velasco, M.; Moreno-Otero, R.; Mate, J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel. Dis, 2007, 13(9), 1106-1114.
144. Gardiner, S.J.; Gearry, R.B.; Burt, M.J.; Ding, S.L.; Barclay, M.L. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur. J. Gastroenterol. Hepatol., 2008, 20(12), 1238-1242.
145. De Boer, N.K.; Mulder, C.J.; Van Bodegraven, A.A. Nodular regenerative hyperplasia and thiopurines: the case for leveldependent toxicity. Liver. Transpl, 2005, 11(10), 1300-1301.
146. Arnott, I.D. and Ghosh, S. Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury. Eur. J. Gastroenterol. Hepatol, 2000, 12(5), 569-573.
147. Haboubi, N.Y.; Ali, H.H.; Whitwell, H.L.; Ackrill, P. Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am. J. Gastroenterol, 1988, 83(3), 256-261.
148. Seiderer, J.; Zech, C.J.; Diebold, J.; Schoenberg, S.O.; Brand, S.; Tillack, C.; Goke, B.; Ochsenkuhn, T. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur. J. Gastroenterol. Hepatol., 2006, 18(5), 553-555.
149. De Boer, N.K.; Tuynman, H.; Bloemena, E.; Westerga, J.; Van Der Peet, D.L.; Mulder, C.J.; Cuesta, M.A.; Meuwissen, S.G.; Van Nieuwkerk, C.M.; Van Bodegraven, A.A. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand. J. Gastroenterol., 2008, 43(5), 604-608.
150. Vernier-Massouille, G.; Cosnes, J.; Lemann, M.; Marteau, P.; Reinisch, W.; Laharie, D.; Cadiot, G.; Bouhnik, Y.; De Vos, M.; Boureille, A.; Duclos, B.; Seksik, P.; Mary, J.Y.; Colombel, J.F. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut, 2007, 56(10), 1404-1409.
151. Mion, F.; Napoleon, B.; Berger, F.; Chevallier, M.; Bonvoisin, S.; Descos, L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut, 1991, 32(6), 715-717.
152. Buster, E.H.; Van Vuuren, H.J.; Zondervan, P.E.; Metselaar, H.J.; Tilanus, H.W.; De Man, R.A. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur. J. Gastroenterol. Hepatol., 2008, 20(1), 68-72.
153. Gane, E.; Portmann, B.; Saxena, R.; Wong, P.; Ramage, J.; Williams, R. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology, 1994, 20(1 Pt 1), 88-94.
154. Breen, D.P.; Marinaki, A.M.; Arenas, M.; Hayes, P.C. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl., 2005, 11(7), 826-833.
155. De Boer, N.K.; Derijks, L.J.; Gilissen, L.P.; Hommes, D.W.; Engels, L.G.; De Boer, S.Y.; Den Hartog, G.; Hooymans, P.M.; Makelburg, A.B.; Westerveld, B.D.; Naber, A.H.; Mulder, C.J.; De Jong, D.J. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J. Gastroenterol., 2005, 11(35), 5540-5544.
156. Derijks, L.J.J.; Gilissen, L.P.L.; Engels, L.G.J.B.; Bos, L.P.; Bus, P.J.; Lohman, J.J.H.M.; Van Deventer, S.J.H.; Hommes, D.W.; Hooymans, P.M. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther. Drug Monit., 2006, 28(1), 45-50.
157. Dubinsky, M.C.; Feldman, E.J.; Abreu, M.T.; Targan, S.R.; Vasiliauskas, E.A. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am. J. Gastroenterol., 2003, 98(5), 1058-1063.
158. Herrlinger, K.R.; Fellermann, K.; Fischer, C.; Kreisel, W.; Deibert, P.; Schoelmerich, J.; Fleig, W.E.; Ruhl, A.; Reinshagen, M.; Greinwald, R.; Stange, E.F.; Schwab, M. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease. Aliment. Pharmacol. Ther., 2004, 19(12), 1269-1276.
159. Bonaz, B.; Boitard, J.; Marteau, P.; Lemann, M.; Coffin, B.; Flourie, B.; Belaiche, J.; Cadiot, G.; Metman, E.H.; Cortot, A.; Colombel, J.F. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/ mercaptopurine. Aliment. Pharmacol. Ther., 2003, 18(4), 401-408.
160. Ansari, A.; Elliott, T.; Fong, F.; Arenas-Hernandez, M.; Rottenberg, G.; Portmann, B.; Lucas, S.; Marinaki, A.; Sanderson, J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel. Dis., 2008, 14(10), 1399-1405.
161. De Boer, N.K.; De Graaf, P.; Wilhelm, A.J.; Mulder, C.J.; Van Bodegraven, A.A. On the limitation of 6-thioguaninenucleotide monitoring during tioguanine treatment. Aliment. Pharmacol. Ther., 2005, 22(5), 447-451.
162. Almer, S.H.; Hjortswang, H.; Hindorf, U. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients. Dig. Liver Dis., 2009, 41(3), 194-200.
163. Teml, A.; Schwab, M.; Hommes, D.W.; Almer, S.; Lukas, M.; Feichtenschlager, T.; Florin, T.; Seiderer, J.; Petritsch, W.; Bokemeyer, B.; Kreisel, W.; Herrlinger, K.R.; Knoflach, P.; Bonaz, B.; Klugmann, T.; Herfarth, H.; Pedarnig, N.; Reinisch, W. A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien. Klin. Wochenschr, 2007, 119(17-18), 519-526.
164. Ferlitsch, A.; Teml, A.; Reinisch, W.; Ulbrich, G.; Wrba, F.; Homoncik, M.; Gangl, A.; Peck-Radosavljevic, M.; Vogelsang, H. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am. J. Gastroenterol., 2007, 102(11), 2495-2503.
165. Gilissen, L.P.; Derijks, L.J.; Driessen, A.; Bos, L.P.; Hooymans, P.M.; Stockbrugger, R.W.; Engels, L.G. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig. Liver Dis., 2007, 39(2), 156-159.
166. De Boer, N.K.; Zondervan, P.E.; Gilissen, L.P.; Den Hartog, G.; Westerveld, B.D.; Derijks, L.J.; Bloemena, E.; Engels, L.G.; Van Bodegraven, A.A.; Mulder, C.J. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig. Liver Dis., 2008, 40(2), 108-113.
167. Jharap, B.; Mulder, C.; Den Hartog, G.; Westerveld, B.D.; Engels, L.G.; De Jong, D.J.; Van Bodegraven, A.A.; De Boer, N.K. Adequately dosed 6-TG use in chronic intestinal inflammation is not associated with nodular regenerative hyperplasia: a series of 73 liver biopsies. J. Crohns Colitis Suppl., 2007, 1(1), 22.
168. Derijks, L.J.; De Jong, D.J.; Gilissen, L.P.; Engels, L.G.; Hooymans, P.M.; Jansen, J.B.; Mulder, C.J. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol., 2003, 15(1), 63-67.
169. Elion, G.B. Enzymatic and metabolic studies with allopurinol. Ann. Rheum. Dis, 1966, 25(6 Suppl), 608-614.
170. Murrell, G.A. and Rapeport, W.G. Clinical pharmacokinetics of allopurinol. Clin. Pharmacokinet, 1986, 11(5), 343-353.
171. Rundles, R.W. Effects of allopurinol on 6-mercaptopurine therapy in neoplastic diseases. Ann. Rheum. Dis., 1966, 25(6 Suppl), 655-656.
172. Zimm, S.; Collins, J.M.; O'Neill, D.; Chabner, B.A.; Poplack, D.G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin. Pharmacol. Ther., 1983, 34(6), 810-817.
173. Venkat Raman, G.; Sharman, V.L.; Lee, H.A. Azathioprine and allopurinol: a potentially dangerous combination. J. Intern. Med., 1990, 228(1), 69-71.
174. Seidel, W. [Panzytopenia from combination therapy with azathioprin and allopurinol]. Z. Rheumatol., 2004, 63(5), 425-427.
175. Bernstein, L.S. The interaction between allopurinol and azathioprine. J. Intern. Med., 1993, 233(5), 426-427.
176. Boyd, I.W. Allopurinol-azathioprine interaction. J. Intern. Med., 1991, 229(4), 386.
177. Kennedy, D.T.; Hayney, M.S.; Lake, K.D. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann. Pharmacother., 1996, 30(9), 951-954.
178. Cummins, D.; Sekar, M.; Halil, O.; Banner, N. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation, 1996, 61(11), 1661-1662.
179. Chocair, P.; Duley, J.; Simmonds, H.A.; Cameron, J.S.; Ianhez, L.; Arap, S.; Sabbaga, E. Low-dose allopurinol plus azathioprine/ cyclosporin/ prednisolone, a novel immunosuppressive regimen. Lancet, 1993, 342(8863), 83-84.
180. Chrzanowska, M. and Krzymanski, M. Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Ther. Drug Monit., 1999, 21(2), 231-237.
181. Sparrow, M.P.; Hande, S.A.; Friedman, S.; Lim, W.C.; Reddy, S.I.; Cao, D.; Hanauer, S.B. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther., 2005, 22(5), 441-446.
182. Duley, J.A.; Chocair, P.R.; Florin, T.H.J. Observations on the use of allopurinol in combination with azathioprine or mercaptopurine. Aliment. Pharmacol. Ther., 2005, 22(11-12), 1161-1162.
183. Sparrow, M.P.; Hande, S.A.; Friedman, S.; Cao, D.; Hanauer, S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol, 2007, 5(2), 209-214.
184. Ansari, A.; Elliott, T.; Baburajan, B.; Mayhead, P.; O'Donohue, J.; Chocair, P.; Sanderson, J.; Duley, J. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther., 2008, 28(6), 734-741.
185. Rahhal, R.M. and Bishop, W.P. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm. Bowel Dis., 2008, 14(12), 1678-1682.
186. Pacher, P.; Nivorozhkin, A.; Szabo, C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev., 2006, 58(1), 87-114.
187. Rahimi, R.; Nikfar, S.; Rezaie, A.; Abdollahi, M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig. Dis. Sci., 2009, 54(4), 712-721.
188. Van Bodegraven, A.A. and Mulder, C.J. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J. Gastroenterol., 2006, 12(38), 6115-6123.
189. Desreumaux, P. and Ghosh, S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment. Pharmacol. Ther., 2006, 24(Suppl.), 2-9.
190. Woodson, L.C.; Ames, M.M.; Selassie, C.D.; Hansch, C.; Weinshilboum, R.M. Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol. Pharmacol., 1983, 24(3), 471-478.
191. Szumlanski, C.L. and Weinshilboum, R.M. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br. J. Clin. Pharmacol., 1995, 39(4), 456-459.
192. Lowry, P.W.; Szumlanski, C.L.; Weinshilboum, R.M.; Sandborn, W.J. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology, 1999, 116(6), 1505-1506.
193. Lewis, L.D.; Benin, A.; Szumlanski, C.L.; Otterness, D.M.; Lennard, L.; Weinshilboum, R.M.; Nierenberg, D.W. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drugdrug interaction. Clin. Pharmacol. Ther., 1997, 62(4), 464-475.
194. Green, J.R. Balsalazide and azathioprine or 6-mercaptopurine. Gastroenterology, 1999, 117(6), 1513-1514.
195. Xin, H.; Fischer, C.; Schwab, M.; Klotz, U. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2005, 21(9), 1105-1109.
196. Lowry, P.W.; Franklin, C.L.; Weaver, A.L.; Szumlanski, C.L.; Mays, D.C.; Loftus, E.V.; Tremaine, W.J.; Lipsky, J.J.; Weinshilboum, R.M.; Sandborn, W.J. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut, 2001, 49(5), 656-664.
197. Dewit, O.; Vanheuverzwyn, R.; Desager, J.P.; Horsmans, Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment. Pharmacol. Ther., 2002, 16(1), 79-85.
198. Gilissen, L.P.L.; Bierau, J.; Derijks, L.J.J.; Bos, L.P.; Hooymans, P.M.; Van Gennip, A.; Stockbrugger, R.W.; Engels, L.G.J.B. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment. Pharmacol. Ther., 2005, 22(7), 605-611.
199. De Boer, N.K.; Wong, D.R.; Jharap, B.; De Graaf, P.; Hooymans, P.M.; Mulder, C.J.; Rijmen, F.; Engels, L.G.; Van Bodegraven, A.A. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am. J. Gastroenterol., 2007, 102(12), 2747-2753.
200. Campbell, S. and Ghosh, S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur. J. Gastroenterol. Hepatol., 2001, 13(11), 1297-1301.
201. Shah, J.A.; Edwards, C.M.; Probert, C.S. Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. Eur. J. Gastroenterol. Hepatol., 2008, 20(3), 169-173.
202. Andrews, J.M.; Travis, S.P.; Gibson, P.R.; Gasche, C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment. Pharmacol. Ther., 2009, 29(5), 459-469.
203. Dervieux, T.; Hancock, M.; Evans, W.; Pui, C.H.; Relling, M.V. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia, 2002, 16(2), 209-212.
204. Bokkerink, J.P.; Bakker, M.A.; Hulscher, T.W.; De Abreu, R.A.; Schretlen, E.D. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem. Pharmacol., 1988, 37(12), 2321-2327.
205. Soon, S.Y.; Ansari, A.; Yaneza, M.; Raoof, S.; Hirst, J.; Sanderson, J.D. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol., 2004, 16(9), 921-926.
206. Roblin, X.; Serre-Debeauvais, F.; Phelip, J.M.; Bessard, G.; Bonaz, B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment. Pharmacol. Ther., 2003, 18(9), 917-925.
207. Peyrin-Biroulet, L.; Cadranel, J.F.; Nousbaum, J.B.; Oussalah, A.; Seddik, M.; Canva, V.; Cortot, A.; Sogni, P.; Gueant, J.L.; Bigard, M.A.; Roblin, X.; Bronowicki, J.P. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment. Pharmacol. Ther., 2008, 28(8), 984-993.
208. Lennard, L. Clinical implications of thiopurine methyltransferase- optimization of drug dosage and potential drug interactions. Ther. Drug Monit., 1998, 20(5), 527-531.
209. Gossmann, J.; Kachel, H.G.; Schoeppe, W.; Scheuermann, E.H. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation, 1993, 56(3), 585-589.
210. McGovern, D.P.; Travis, S.P.; Duley, J.; Shobowale-Bakre, E.M.; Dalton, H.R. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity. Gastroenterology, 2002, 122(3), 838-839.
211. Lees, C.W.; Maan, A.K.; Hansoti, B.; Satsangi, J.; Arnott, I.D. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther., 2008, 27(3), 220-227.
212. Dubinsky, M.C.; Hassard, P.V.; Seidman, E.G.; Kam, L.Y.; Abreu, M.T.; Targan, S.R.; Vasiliauskas, E.A. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis., 2001, 7(3), 181-189.
213. De Boer, N.K.; Reinisch, W.; Teml, A.; Van Bodegraven, A.A.; Schwab, M.; Lukas, M.; Ochsenkuhn, T.; Petritsch, W.; Knoflach, P.; Almer, S.; Van der Merwe, S.W.; Herrlinger, K.R.; Seiderer, J.; Vogelsang, H.; Mulder, C.J. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion, 2006, 73(1), 25-31.
214. Sandborn, W.J. Rational dosing of azathioprine and 6-mercaptopurine. Gut, 2001, 48(5), 591-592.
215. Kaskas, B.A.; Louis, E.; Hindorf, U.; Schaeffeler, E.; Deflandre, J.; Graepler, F.; Schmiegelow, K.; Gregor, M.; Zanger, U.M.; Eichelbaum, M.; Schwab, M. Safe treatment of thiopurine Smethyltransferase deficient Crohn's disease patients with azathioprine. Gut, 2003, 52(1), 140-142.
216. De Boer, N.K.; Mulder, C.J.; Van Bodegraven, A.A. Impracticalities of thiopurine S-methyltransferase determination in daily inflammatory bowel disease practice. Aliment. Pharmacol. Ther., 2006, 23(8), 1278-1279.
217. Dubinsky, M.C. and Sandborn, W.J. Optimizing thiopurine response in IBD: The clinical utility of TPMT testing and metabolite monitoring. Gastroenterol. Hepatol., 2006, 2(8), 1-8.